MEDICAL DEFENSE AGAINST BIOLOGICAL MATERIAL

File: 121096_sep96_decls28_0019.txt
Page: 0019
Total Pages: 23

Subject: MEDICAL DEFENSE AGAINST BIOLOGICAL MATERIAL                     

Unit: OTSG        

Parent Organization: HSC         

Box  ID: BX003202

Folder Title: DOCUMENT LISTING FOR PROJECT BADGER                                                             

Document Number:          3

Folder Seq  #:          1


                                         UNCLASSIFIED








          organisms by aerosol or intradermal routes), ulceroglandular,
          typhoidal or pharyngeal forms could be seen. Ulceroglandular
          tularemia generally occurs about 3 days after exposure (range,
          2-10 days), and manifests as a cutaneous ulcer with regional
          lymphadenopathy, fever, chills, headache, and malaise. With
          typhoidal disease, the systemic clinical manifestations are
          similar to those seen in the ulceroglandular form, but the
          disease is not "contained" as a localized lesion. Typhoidal
          disease occurs after inhalation of tularemia organisms; in the
          latter, clinically and radiologically evident pneumonia may be
          significant. Three to five days following inhalation, the
          abrupt onset of fever, chills, headache, myalgia, and
          prostration are seen, with a non-productive cough. Deposition
          of organisms in the orophyarynx may also produce a pharynygeal
          form of tularemia, with "ulceroglandular" type lesions
          localized to the throat.



          DILQNOSIS

               Specific Laboratory Diagnosis. Identification of
            organisms by staining ulcer fluids or sputum is generally
            not helpful. Routine culture is difficult due to unusual
            growth requirements or overgrowth of commensual bacteria.
            The diagnosis can be established retrospectively by serology.


               -X. Streptomycin is the treatment of choice. Gentamycin
          is also effective. Although laboratory-related infections with
          this organism are very common, human-to-human spread is unusual.


                     . A live-attenuated tularemia vaccine is available
          as in investigational new drug (IND). This vaccine has been
          administered to more than 5,000 persons without significant
          adverse reactions, and is of proven effectiveness in preventing
tory-acquired typhoidal and pneumonic tularemia.

            The use of antibiotics for prophylaxis against tularemia is
          controversial. At best, onset of disease will be delayed
          somewhat.








                                         16



                                       UNCLASSIFIED

Document 23 f:/Week-36/BX003202/DOCUMENT LISTING FOR PROJECT BADGER/medical defense against biological material:12069615355829
Control Fields 17
File Room = sep96_declassified
File Cabinet = Week-36
Box ID = BX003202
Unit = OTSG
Parent Organization = HSC
Folder Title = DOCUMENT LISTING FOR PROJECT BADGER
Folder Seq # = 1
Subject = MEDICAL DEFENSE AGAINST BIOLOGICAL MATERIAL
Document Seq # = 3
Document Date =
Scan Date =
Queued for Declassification = 01-JAN-1980
Short Term Referral = 01-JAN-1980
Long Term Referral = 01-JAN-1980
Permanent Referral = 01-JAN-1980
Non-Health Related Document = 01-JAN-1980
Declassified = 06-DEC-1996